The number of class action lawsuits filed against Indian pharmaceutical companies has gone up in recent times. With the US law firms alleging non-disclosure of investor sensitive information, pay-for-delay conspiracies among other violations by these companies.
As many as six drug companies or subsidiaries of the parent generic drug firms from India were named in an over a dozen class action lawsuits for alleged violation of American federal securities laws and anti trust laws either individually or in a group comprising drug companies, including those from other countries.
In a few instances the companies have settled the matter by reaching